Tango Therapeutics (TNGX) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 116.7% versus a loss of 1.3%. Over five years, TNGX leads with a +110.0% price change compared with +63.7% for VRDN. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.40 billion), about 1.1 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs +48.3%).
Tango Therapeutics converts more of its revenue into profit, with a net margin of -162.9% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TNGX | VRDN |
|---|---|---|
| Share price | $21.73 | $29.96 |
| Market cap | $3.68B | $3.40B |
| 1-day change | -4.32% | -4.71% |
| YTD return | +145.26% | -3.73% |
| 1-year return | +116.65% | -1.25% |
| 5-year return | +109.95% | +63.72% |
| EPS (TTM) | $-1.38 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $62.38M | $70.85M |
| Revenue growth (YoY) | +48.29% | +23359.93% |
| Net income (latest FY) | $-101.59M | $-342.60M |
| Operating margin | -178.39% | -512.91% |
| Net margin | -162.85% | -483.57% |
| 52-week high | $34.39 | $34.29 |
| 52-week low | $8.30 | $13.18 |
| Distance from 52-week high | -36.81% | -12.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +116.29% | +42.72% |
| Average volume | 3.41M | 2.14M |
| Shares outstanding | 169.46M | 113.56M |
| Employees | 137 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed VRDN by 117.9 percentage points over the past year.
- Tango Therapeutics is more profitable, keeping -162.9 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +48.29%).
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
TNGX vs VRDN FAQ
Which is bigger, Tango Therapeutics or Viridian Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.40B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, TNGX or VRDN?
TNGX returned +116.65% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Tango Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.